Skip Navigation


JAC Advance Access originally published online on August 6, 2009
Journal of Antimicrobial Chemotherapy 2009 64(4):782-785; doi:10.1093/jac/dkp278
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
64/4/782    most recent
dkp278v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Feese, E.
Right arrow Articles by Ghiladi, R. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feese, E.
Right arrow Articles by Ghiladi, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Highly efficient in vitro photodynamic inactivation of Mycobacterium smegmatis

Elke Feese and Reza A. Ghiladi*

Department of Chemistry, North Carolina State University, Raleigh, NC 27695, USA

Received 7 February 2009; returned 21 April 2009; revised 8 July 2009; accepted 9 July 2009

* Corresponding author. Tel: +1 919-513-0680; Fax: +1 919-515-5079; E-mail: Reza_Ghiladi{at}NCSU.edu

Objectives: Efforts to control tuberculosis (TB) have been hampered by the emergence of multiple-drug resistant strains, necessitating pursuit of alternative approaches to the current antibiotic-based treatments. Herein, we explore the feasibility of photodynamic inactivation (PDI) of mycobacteria.

Methods: In vitro PDI studies employing Mycobacterium smegmatis as a surrogate for Mycobacterium tuberculosis were performed examining photosensitizer (PS) type, concentration and light dose. M. smegmatis was grown to a concentration of 108 colony forming units (cfu) per mL, resuspended in PBS–0.5% Tween-80-containing buffer, incubated with the PS for 5 min and subsequently illuminated with white light (400–700 nm) at a fluence rate of 60 mW/cm2 for 1, 5, 15 or 30 min (equivalent to 3.4, 18, 54 or 108 J/cm2). The percentage survival was determined by the ratio of the colony count from illuminated and non-illuminated control cell suspensions. The PSs examined were 5,10,15,20-tetrakis(1-methyl-4-pyridinyl)porphyrin tetratosylate (TMPyP), 5,10,15,20-tetrakis(4-N,N,N-trimethylanilinium)porphyrin tetrachloride (TNMAP), methylene blue (MB), 5,10,15,20-tetrakis(4-sulphonatophenyl)porphyrin (TSPP), 5,10,15,20-tetrakis(4-carboxyphenyl)porphyrin-Pd(II) (TCPP-Pd) and phthalocyanine tetrasulphonic acid (PhCS).

Results: Our best results demonstrate that PDI of M. smegmatis can achieve a noteworthy 5–6 log unit reduction in cfu (99.999% + viable cell eradication) when cationic PSs are employed in the nanomolar concentration range. Anionic PSs did not effectively mediate PDI of mycobacteria due to their inability to associate with the negatively charged mycobacterial cell membrane.

Conclusions: PDI of M. smegmatis was found to be highly efficient in reducing the number of viable cells in vitro when cationic PSs were employed.

Keywords: multidrug resistant , TB , photosensitizers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.